stockrow
Saturday 7 November 2026
Export IBO’s income statement to Excel — free account
Impact Biomedical Inc.
Impact Biomedical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32,000.00, down 36.0% from fiscal 2022.
- Revenue
- −57.1%
- EPS
- +99.5%
- Free cash flow
- +167.7%
Quarter to June 2026, against a year earlier
4.10
0.30
−6.82%
Follow IBO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(348.23%) | (104.15%) | (119.83%) | 24.01% | |
| (136.16%) | (62.81%) | (69.25%) | 4.41% | ||
ROIC |
0.00% | (17.21%) | (23.66%) | (22.81%) | |
Return on Tangible Assets |
193.27% | 1,576.30% | 981.53% | (45.74%) | |
Average Days of Receivables |
0.00 | 22.26 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.08) | (0.27) | (0.20) | (0.06) | |
Free Cash Flow |
(2.97) | (1.89) | (1.67) | (0.51) | |
| Other line items | |||||
Cash ROIC |
33.65% | (12.15%) | (11.35%) | (3.62%) | |
Accounts Receivable Turnover |
0.00 | 1.23 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.83 | |
Inventory Turnover |
— | — | 0.00 | 1.55 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 401.07 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 53.25 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 414.63% | 725.64% | 811.43% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,093.90% | 5,771.79% | 6,202.86% | |
Share Based Compensation of Revenue |
0.00% | 15.85% | 3,646.15% | 3,597.14% | |
Interest Coverage |
(27.63) | (5.40) | — | — | |
Operating CF/Net income |
0.07 | 0.16 | 0.13 | (0.64) | |
Depreciation/Fixed assets |
2,017.77 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
(3.08) | (0.27) | (0.20) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026